To study the effect of high dose Atorvastatin 40mg versus 80mg in patients with dyslipidemia

Deepak Agrawal, S C Manchanda, J P S Sawhney, Bhuwanesh Kandpal, Rajneesh Jain, Ashwani Mehta, Arun Mohanty, Rajiv Passey, Aman Makhija, Manish Kr Sharma, Deepak Agrawal, S C Manchanda, J P S Sawhney, Bhuwanesh Kandpal, Rajneesh Jain, Ashwani Mehta, Arun Mohanty, Rajiv Passey, Aman Makhija, Manish Kr Sharma

Abstract

Objective: Primary objective was to compare the effects of atorvastatin 40mg vs 80mg on LDL-C in Indian patients with atherosclerotic dyslipidemia. Secondary objectives were to compare the effects of atorvastatin 40mg vs 80mg on HDL-C and triglycerides and also comparing of side effects (myopathy, hepatotoxicity and new onset diabetes mellitus) of both doses.

Method: This Study is A Prospective, randomized, open-label, comparative study. This study was conducted on 240 patients of dyslipidemia (as per ACC/AHA 2013 lipid guidelines) attending the OPD/wards/CCU of department of cardiology, Sir Ganga Ram Hospital. They were randomly divided into 2 groups of 120 each. Group A consisted patients who received Atorvastatin 40mg daily and Group B Atorvastatin 80mg daily. The follow up period was 6 months.

Results: At 3 and 6 month follow up, Atorvastatin 40mg leads to mean LDL cholesterol reduction of 47.18±20.81 & 50.03±18.06 respectively. While Atorvastatin 80mg results in LDL reduction as 50.11±15.85 & 52.30±13.72. The comparison between two doses revealed a non-significant difference (p=.118 & p=.149 respectively). At 6 months of follow up, few patients reported myalgia (2 in group A and 7 in Group B). The difference between groups was significant (p=.045). Although none of our patient had significant elevation of CPK.

Conclusion: This study concluded that both doses of atorvastatin (40 & 80mg) are equally efficacious in improving dyslipidemia but higher dose leads to more incidence of myalgia.

Keywords: Atherosclerosis; Atorvastatin; Dyslipidemia; Myalgia.

Copyright © 2018. Published by Elsevier B.V.

Figures

Fig. 1
Fig. 1
Randomization and follow up.

References

    1. Enas E.A., Salim Yusuf Mehta J.L. Prevalence of coronary artery disease in Asian Indians. Am J Cardiol. 2018;70:945–949.
    1. Grundy S.M. Small LDL, atherogenic dyslipidemia and the metabolic syndrome. Circulation. 1997;95:1–4.
    1. Haffnar M. Diabetes, hyperlipidemia and coronary artery disease. Am J Cardiol. 1999;83:17F–21F. [Supplement]
    1. Joshi S.R., Anjana R.M., Deepa M. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PLoS One. 2014;9:e96808.
    1. Newman C., Tsai J., Szarek M. Comparative safety of atorvastatin 80 mg vs 10 mg derived from analysis of 49 completed trials in 14236 patients. Am J Cardiol. 2006;97:61–67.
    1. Ridker P.M., Danielson E., Fonseca F.A. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med. 2008;359:2195–2207.
    1. Kanda M., Satoh K., Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull. 2003;26:1681–1684.
    1. Bruckert E., Hayem G., Dejager S. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovas Drugs Ther. 2005;19(December (6)):403–414.
    1. Preiss D., Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol. 2011;22:460–466.
    1. Waters D.D., Ho J.E., DeMicco D.A. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57:1535–1545.
    1. Stone N.J., Robinson J.G., Lichtenstein A.H. 2013 ACC/AHA Cholesterol Guideline Panel: treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med. 2014;160:339–343.
    1. Deedwania P.C., Gupta M., Stein M. Comparison of rosuvastatin versus atorvastatin in south Asian patients at risk of coronary heart disease (from the IRIS Trial) Am J Cardiol. 2007;99:1538–1543.
    1. Kaul U., Varma J., Kahali D. Post marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in indian patients with acute coronary syndrome- a randomized, multicenter study (CURE-ACS) J Assoc Phys India. 2013;61:97–101.
    1. Philip Barter J., Gunnar Brandrup-Wognsen Mike Palmer K. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res. 2010;51(June (6)):1546–1553.
    1. Jones P.H., Davidson M.H., Stein E.A. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) Am J Cardiol. 2003;92:152–160.
    1. Aleesa A.C., Gomes Tara, Camacho Ximena. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610.
    1. Jones Peter H., McKenney James M., Karalis Dean G. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia -NASDAC Study. Am Heart J. 2005;149(January (1)):e1.
    1. Parker Beth A., Capizzi Jeffrey A., Grimaldi Adam S. Effect of statins on skeletal muscle function and performance. Circulation. 2013;127:96–103.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다